益丰药房(603939) - 2025 Q3 - 季度财报

Financial Performance - Total revenue for Q3 2025 reached CNY 5,564,080,298.18, an increase of 1.97% compared to the same period last year[3] - Net profit attributable to shareholders was CNY 344,509,955.35, reflecting a growth of 10.14% year-over-year[3] - The total profit for the period was CNY 506,365,892.34, up by 12.90% from the previous year[3] - Basic earnings per share for the quarter stood at CNY 0.28, a rise of 7.69% compared to the same quarter last year[4] - Total operating revenue for the first three quarters of 2025 reached ¥19,024,372,147.87, an increase from ¥18,703,468,518.23 in the same period of 2024, reflecting a growth of approximately 1.71%[23] - Net profit attributable to shareholders of the parent company was ¥1,224,555,838.55, up from ¥1,110,500,691.55, representing an increase of about 10.26%[20] - Operating profit for the period was ¥1,786,801,453.44, compared to ¥1,585,544,439.53, indicating a growth of approximately 12.67%[19] - Total comprehensive income for the period was ¥1,368,940,098.23, compared to ¥1,109,047,791.02, marking an increase of about 23.39%[20] - Basic earnings per share increased to ¥1.01 from ¥0.92, reflecting a growth of approximately 9.78%[20] Cash Flow and Investments - The net cash flow from operating activities for the year-to-date period was CNY 2,267,211,017.81, down by 32.16%[3] - The net cash flow from operating activities decreased to ¥2,267,211,017.81 from ¥3,341,774,378.18, a decline of about 32.23%[23] - The net cash flow from investing activities was -363,176,077.84, compared to -3,670,397,674.23 in the previous period, indicating a significant improvement[24] - The net cash flow from financing activities was -2,075,775,121.25, a substantial increase in outflow compared to -90,663,355.34 last year[24] - Cash outflow for investing activities totaled 22,981,387,474.34, compared to 16,089,737,685.38 in the prior period, reflecting increased investment[24] - Cash outflow for financing activities was 2,077,528,121.25, up from 1,901,026,355.34, indicating higher financing costs[24] - The cash inflow from investment activities was 22,618,211,396.50, compared to 12,419,340,011.15 in the previous period, showing a significant increase[24] - The company reported a cash outflow of 914,684,834.87 for dividend distribution, which increased from 604,739,986.11 last year[24] - The cash and cash equivalents decreased by 171,740,181.28 during the period, compared to a decrease of 419,286,651.39 in the previous year[24] Assets and Liabilities - The company's total assets decreased by 6.80% to CNY 26,071,387,113.50 compared to the end of the previous year[4] - As of September 30, 2025, the total assets of the company amounted to RMB 26,071,387,113.50, a decrease from RMB 27,974,736,950.35 at the end of 2024, representing a decline of approximately 6.8%[14] - The company's total liabilities decreased to RMB 14,188,944,678.91 from RMB 16,581,173,472.42, indicating a reduction of about 14.4%[16] - The cash and cash equivalents as of September 30, 2025, were RMB 3,118,997,451.69, down from RMB 3,578,925,577.22, reflecting a decrease of approximately 12.9%[14] - The company's total equity increased to RMB 11,882,442,434.59 from RMB 11,393,563,477.93, marking an increase of approximately 4.3%[16] - The company's accounts receivable decreased to RMB 1,469,423,541.96 from RMB 2,123,984,911.43, a decline of about 30.8%[14] - The company's short-term borrowings decreased to RMB 20,017,777.78 from RMB 30,026,388.89, a reduction of approximately 33.5%[15] - The company's long-term borrowings remained stable, with total bonds payable at RMB 1,638,776,478.50, slightly increasing from RMB 1,601,308,876.07[16] Store Operations - The company opened 137 new stores and closed 440 stores in the first nine months of 2025, resulting in a total of 14,666 stores at the end of the reporting period, a net decrease of 18 stores year-over-year[13] - The company reported a total of 4,097 franchise stores included in the total store count as of September 30, 2025[13] Other Financial Metrics - Non-recurring gains and losses for the quarter totaled CNY 13,704,329.41, with a year-to-date total of CNY 36,632,913.44[7] - The weighted average return on equity was 3.35% for the quarter, compared to 11.05% in the previous year[4] - Research and development expenses were ¥21,511,803.30, down from ¥25,185,648.10, showing a decrease of approximately 14.66%[19] - Total operating costs decreased to ¥15,631,502,380.85 from ¥15,712,009,022.92, a reduction of about 0.51%[19] - Other income increased to ¥52,760,114.25 from ¥40,942,345.23, representing a growth of approximately 28.93%[19] - The company reported a net investment income of ¥99,769,501.43, up from ¥76,803,405.41, indicating an increase of about 30.00%[19] Accounting Standards - The company did not apply new accounting standards starting from 2025[25]